Catalyst Pharmaceuticals (CPRX) Research & Development (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly Research & Development of $2.7 million for Q1 2026, down 31.54% year-on-year from $3.9 million in Q1 2025, and up 47.26% on a QoQ basis from $1.8 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 17 years of Research & Development data on file, last reported at $2.7 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 31.54% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (down 17.71% YoY), and the FY2025 full-year result was $12.7 million, changed 0.48% from the prior year.
- Research & Development for Q1 2026 stood at $2.7 million, up from $1.8 million in the prior quarter.
- Across five years, Research & Development topped out at $83.7 million in Q3 2023 and bottomed at $1.8 million in Q4 2025.
- The 5-year median for Research & Development is $3.6 million (2023), against an average of $8.3 million.
- The widest annual swing landed in 2023, when Research & Development surged 906.76%; it then sank 96.07% in 2024.
- A 5-year view of Research & Development shows it stood at $4.1 million in 2022, then tumbled by 51.82% to $2.0 million in 2023, then soared by 92.6% to $3.8 million in 2024, then slumped by 52.42% to $1.8 million in 2025, then soared by 47.26% to $2.7 million in 2026.
- The last three Research & Development figures came in at $2.7 million (Q1 2026), $1.8 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 2.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.66 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 4.36 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.28 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Dec 31, 2023 | 1.97 Mn |
| Sep 30, 2023 | 83.66 Mn |
| Jun 30, 2023 | 3.95 Mn |
| Mar 31, 2023 | 3.56 Mn |
| Dec 31, 2022 | 4.09 Mn |
| Sep 30, 2022 | 8.31 Mn |
| Jun 30, 2022 | 3.98 Mn |
| Mar 31, 2022 | 3.40 Mn |
| Dec 31, 2021 | 4.99 Mn |
| Sep 30, 2021 | 4.49 Mn |
| Jun 30, 2021 | 4.45 Mn |
| Mar 31, 2021 | 3.01 Mn |
| Dec 31, 2020 | 4.18 Mn |
| Sep 30, 2020 | 3.75 Mn |
| Jun 30, 2020 | 4.35 Mn |
| Mar 31, 2020 | 4.22 Mn |
| Dec 31, 2019 | 6.31 Mn |
| Sep 30, 2019 | 4.60 Mn |
| Jun 30, 2019 | 4.63 Mn |
| Mar 31, 2019 | 3.31 Mn |
| Dec 31, 2018 | 8.42 Mn |
| Sep 30, 2018 | 4.54 Mn |
| Jun 30, 2018 | 3.70 Mn |
| Mar 31, 2018 | 3.26 Mn |
| Dec 31, 2017 | 3.40 Mn |
| Sep 30, 2017 | 2.70 Mn |
| Jun 30, 2017 | 2.45 Mn |
| Mar 31, 2017 | 2.81 Mn |
| Dec 31, 2016 | 2.82 Mn |
| Sep 30, 2016 | 2.49 Mn |
| Jun 30, 2016 | 2.51 Mn |
| Mar 31, 2016 | 3.55 Mn |
| Dec 31, 2015 | 3.83 Mn |
| Sep 30, 2015 | 3.04 Mn |
| Jun 30, 2015 | 2.58 Mn |
| Mar 31, 2015 | 2.35 Mn |
| Dec 31, 2014 | 2.38 Mn |
| Sep 30, 2014 | 2.89 Mn |
| Jun 30, 2014 | 2.10 Mn |
| Mar 31, 2014 | 2.75 Mn |
| Dec 31, 2013 | 2.07 Mn |
| Sep 30, 2013 | 2.80 Mn |
| Jun 30, 2013 | 2.13 Mn |
| Mar 31, 2013 | 1.09 Mn |
| Dec 31, 2012 | 744,692.00 |
| Sep 30, 2012 | 654,837.00 |
| Jun 30, 2012 | 532,741.00 |
| Mar 31, 2012 | 727,327.00 |
| Dec 31, 2011 | 960,240.00 |
| Sep 30, 2011 | 614,137.00 |
| Jun 30, 2011 | 905,635.00 |
| Mar 31, 2011 | 903,953.00 |
| Dec 31, 2010 | 569,168.00 |
| Sep 30, 2010 | 500,091.00 |